SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions SIOUX FALLS, S.D. and GAITHERSBURG, Md., Oct. 27, 2022 (GLOBE NEWSWIRE) — SAB Biotherapeutics...
New Data Presented at ISPOR 2022 Analyzes the Real-world Economic Burden of Prescription Opioid Overdose and Use of Naloxone in the United States Using a Large Healthcare Claims Database
New Data Presented at ISPOR 2022 Analyzes the Real-world Economic Burden of Prescription Opioid Overdose and Use of Naloxone in the United States Using a Large Healthcare Claims Database As...
Emergent Hires New Chief Ethics and Compliance Officer
Emergent Hires New Chief Ethics and Compliance Officer We are pleased to announce that starting May 2, Joseph Philipose is joining Emergent as Senior Vice President and Chief Ethics and Compliance...
Reverse the Silence Campaign Releases New Broadcast Segments About Opioid Overdose Preparedness and Stigma
Reverse the Silence Campaign Releases New Broadcast Segments About Opioid Overdose Preparedness and Stigma With the alarming rates of opioid overdose deaths occurring across our country, an alliance...
Preparing for Tomorrow’s Public Health Emergency
Preparing for Tomorrow’s Public Health Emergency For more than two decades, Emergent has been hard at work helping prepare our nation and other allied countries in the event of a public health...
Emergent Adds Quality, CDMO Leaders
Emergent Adds Quality, CDMO Leaders Over the next few weeks, Emergent will add two senior leaders to its Quality and Compliance and Contract Development & Manufacturing (CDMO)...
Emergent Debuts New Campaign During Bowl Season
Emergent Debuts New Campaign During Bowl Season Emergent was pleased to debut our new campaign during the 2021 college football bowl season through a partnership with the Military Bowl to benefit our...
Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study
Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose...
Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks
Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Sponsored by Emergent, Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use...
Emergent BioSolutions CEO: ‘Confrontational’ coverage of vaccine maker puts a target on ‘people doing good’ | COMMENTARY
As the CEO of a 2,000-plus person Maryland-based company involved in the COVID-19 response, I have a high tolerance for the obligations that come with it — like spending endless hours trying to...
Emergent BioSolutions CEO Robert G. Kramer Appointed to Manufacturers Association Board
Emergent BioSolutions’ president and chief executive officer, Robert G. Kramer, has been named to the National Association of Manufacturers (NAM) Board of Directors. Kramer will join the NAM Board...
Workers Producing the Vaccine Need Vaccination
Emergent BioSolutions President and CEO Bob Kramer writes in The Wall Street Journal that the people manufacturing vaccines should be prioritized to receive them. Read what he says here. In the...